See the winner of the 2018 Best of ATS Video Lecture Series: Penn PET Project: Evidence-Based Inhaler Therapy for #COPD
Saturday, April 28, 2018
Saturday, April 21, 2018
Triple versus Dual Inhaler Therapy in Patients with COPD - IMPACT Trial can change COPD Guidelines in 2019
The Informing the Pathway of COPD Treatment (IMPACT) trial, now reported in the The New England Journal of Medicine,
aims to fill this gap with a report on the effectiveness of
LAMA–LABA–inhaled glucocorticoid treatment, contained in a single
inhaler, in COPD.
Background
The benefits
of triple therapy for chronic obstructive pulmonary disease (COPD) with an
inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a
long-acting β2-agonist
(LABA), as compared with dual therapy (either inhaled glucocorticoid–LABA or
LAMA–LABA), are uncertain.
Methods
In this
randomized trial involving 10,355 patients with COPD, we compared 52 weeks of a
once-daily combination of fluticasone furoate (an inhaled glucocorticoid) at a
dose of 100 μg, umeclidinium (a LAMA) at a dose of 62.5 μg, and vilanterol (a LABA) at
a dose of 25 μg (triple therapy) with fluticasone furoate–vilanterol (at doses of 100 μg and 25 μg,
respectively) and umeclidinium–vilanterol (at doses of 62.5 μg and 25 μg,
respectively). Each regimen was administered in a single Ellipta inhaler. The
primary outcome was the annual rate of moderate or severe COPD exacerbations
during treatment.
Results
The rate of
moderate or severe exacerbations in the triple-therapy group was 0.91 per year,
as compared with 1.07 per year in the fluticasone furoate–vilanterol group
(rate ratio with triple therapy, 0.85; 95% confidence interval [CI], 0.80 to
0.90; 15% difference; P<0.001) and 1.21 per year in the
umeclidinium–vilanterol group (rate ratio with triple therapy, 0.75; 95% CI,
0.70 to 0.81; 25% difference; P<0.001). The annual rate of severe
exacerbations resulting in hospitalization in the triple-therapy group was
0.13, as compared with 0.19 in the umeclidinium–vilanterol group (rate ratio,
0.66; 95% CI, 0.56 to 0.78; 34% difference; P<0.001). There was a higher
incidence of pneumonia in the inhaled-glucocorticoid groups than in the
umeclidinium–vilanterol group, and the risk of clinician-diagnosed pneumonia
was significantly higher with triple therapy than with umeclidinium–vilanterol,
as assessed in a time-to-first-event analysis (hazard ratio, 1.53; 95% CI, 1.22
to 1.92; P<0.001).
Conclusions
Triple
therapy with fluticasone furoate, umeclidinium, and vilanterol resulted in a
lower rate of moderate or severe COPD exacerbations than fluticasone
furoate–vilanterol or umeclidinium–vilanterol in this population. Triple
therapy also resulted in a lower rate of hospitalization due to COPD than
umeclidinium–vilanterol.
full text:
Sunday, April 15, 2018
Higher cigarette prices would help millions avoid poor health and extreme poverty
According to a study published in the these days in BMJ, a significant increase
in prices of cigarette would aid millions of people at the global level to avoid
poor health and extreme poverty.
Objective To examine the impact of a 50% increase in market prices of cigarettes on health, poverty, and financial protection.
Objective To examine the impact of a 50% increase in market prices of cigarettes on health, poverty, and financial protection.
Design Compartmental model study.
Setting 13 middle income countries, totalling two billion men.
Participants 500 million male smokers.
Main outcome measures
Life years gained, averted treatment costs, number of men avoiding
catastrophic healthcare expenditures and poverty, and additional tax
revenue by income group.
Results
A 50% increase in cigarette prices would lead to about 450 million
years of life gained across the 13 countries from smoking cessation,
with half of these in China. Across all countries, men in the bottom
income group (poorest 20% of the population) would gain 6.7 times more
life years than men in the top income group (richest 20% of the
population; 155 v 23 million). The average life years gained
from cessation for each smoker in the bottom income group was 5.1 times
that of the top group (1.46 v 0.23 years). Of the $157bn
(£113bn; €127bn) in averted treatment costs, the bottom income group
would avert 4.6 times more costs than the top income group ($46bn v
$10bn). About 15.5 million men would avoid catastrophic health
expenditures in a subset of seven countries without universal health
coverage. As result, 8.8 million men, half of them in the bottom income
group, would avoid falling below the World Bank definition of extreme
poverty. These 8.8 million men constitute 2.4% of people living in
extreme poverty in these countries. In contrast, the top income group
would pay twice as much as the bottom income group of the $122bn
additional tax collected. Overall, the bottom income group would get 31%
of the life years saved and 29% each of the averted disease costs and
averted catastrophic health expenditures, while paying only 10% of the
additional taxes.
Conclusions
Higher prices of cigarettes provide more health and financial gains to
the poorest 20% than to the richest 20% of the population. Higher excise
taxes support the targets of the sustainable development goals on
non-communicable diseases and poverty, and provides financial protection
against illness.
What is already known on this topic
- Higher excise taxes on tobacco are essential to reach the sustainable development goals to reduce mortality from non-communicable diseases by one third by 2030
- Low income groups are more responsive to price increases than high income groups
- There are few published studies of the distributional impact of higher tobacco taxes on health and financial outcomes
What this study adds
- Despite differences in socioeconomic class and health finance arrangements a 50% increase in tobacco prices strongly favours those in the bottom income group for life years saved, out-of-pocket expenses from tobacco attributable treatment costs averted, and avoidance of catastrophic health expenditures or poverty
- Higher tobacco excise taxes are a powerful but generally underused tool by most governments to reduce expenditures on treatment of diseases that are a major cause of income poverty
- In 13 middle income countries studied, around 450 million life years would be saved from higher excise taxes, contributing substantially to the target of the sustainable development goals of a one third reduction in mortality from non-communicable diseases at ages 30-69 by 2030
Saturday, April 7, 2018
Emerging biological therapies for treating eosinophilic COPD
In Pulmonary Pharmacology & Therapeutics was published meta-analysis by great Italian team on hot topic Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis.
Inflammation in COPD is often corticosteroid resistant and, thus, alternative
anti-inflammatory approaches are needed. Since it is still not clear
whether blocking specific pro-inflammatory factors may provide clinical
benefit in COPD, we have performed a meta-analysis to quantify the
impact of monoclonal antibodies (mABs) targeting the
cytokine/chemokine-mediated inflammation in COPD.
A
pairwise and network meta-analyses were performed by extracting data
from randomized clinical trials on COPD concerning the impact of mABs
vs. placebo on the risk of exacerbation, forced expiratory volume in 1 s
(FEV1), and St. George's Respiratory Questionnaire (SGRQ).
Data
on the interleukin (IL)-1β antagonist canakinumab, IL-1R1 antagonist
MEDI8986, IL-5 antagonist mepolizumab, IL-5R antagonist benralizumab,
IL-8 antagonist ABX-IL8, and TNF-α antagonist infliximab were found.
Overall, mAB therapy had a moderate impact on the risk exacerbation, but
not on FEV1 and SGRQ. The pairwise meta-analysis performed
in eosinophilic patients, and the network approach, indicated that
mepolizumab elicited a beneficial effect against the risk of
exacerbation, whereas benralizumab was more effective in improving both
FEV1 and SGRQ.
This study demonstrates that targeting the pathway activated by IL-5 may have a beneficial impact in eosinophilic COPD patients.
Full text:
Saturday, March 31, 2018
Its time to revise Asthma Guidelines? Single maintenance and reliever therapy (SMART) decrease asthma exacerbations
Importance
Combined use of inhaled corticosteroids and long-acting
β-agonists (LABAs) as the controller and the quick relief therapy termed
single maintenance and reliever therapy (SMART) is a potential therapeutic regimen for the management of persistent asthma.
Objective
To conduct a systematic review and meta-analysis of the effects of SMART in patients with persistent asthma.
Data Sources and Study Selection
The databases of MEDLINE via OVID, EMBASE, the Cochrane
Central Register of Controlled Trials, and the Cochrane Database of
Systematic Reviews were searched from database inception through August
2016 and updated through November 28, 2017. Two reviewers selected
randomized clinical trials or observational studies evaluating SMART vs
inhaled corticosteroids with or without a LABA used as the controller
therapy and short-acting β-agonists as the relief therapy for patients
aged 5 years or older with persistent asthma and reporting on an outcome
of interest.
Data Extraction and Synthesis
Meta-analyses were conducted using a random-effects model to
calculate risk ratios (RRs), risk differences (RDs), and mean
differences with corresponding 95% CIs. Citation screening, data
abstraction, risk assessment, and strength of evidence grading were
completed by 2 independent reviewers.
Main Outcomes and Measures
Asthma exacerbations.
Results
The analyses included 16 randomized clinical trials
(N = 22 748 patients), 15 of which evaluated SMART as a combination
therapy with budesonide and formoterol in a dry-powder inhaler. Among
patients aged 12 years or older (n = 22 524; mean age, 42 years; 14 634
[65%] were female), SMART was associated with a reduced risk of asthma
exacerbations compared with the same dose of inhaled corticosteroids and
LABA as the controller therapy (RR, 0.68 [95% CI, 0.58 to 0.80]; RD,
−6.4% [95% CI, −10.2% to −2.6%]) and a higher dose of inhaled
corticosteroids and LABA as the controller therapy (RR, 0.77 [95% CI,
0.60 to 0.98]; RD, −2.8% [95% CI, −5.2% to −0.3%]). Similar results were
seen when SMART was compared with inhaled corticosteroids alone as the
controller therapy. Among patients aged 4 to 11 years (n = 341; median
age, 8 [range, 4-11] years; 69 [31%] were female), SMART was associated
with a reduced risk of asthma exacerbations compared with a higher dose
of inhaled corticosteroids as the controller therapy (RR, 0.55 [95% CI,
0.32 to 0.94]; RD, −12.0% [95% CI, −22.5% to −1.5%]) or the same dose of
inhaled corticosteroids and LABA as the controller therapy (RR, 0.38
[95% CI, 0.23 to 0.63]; RD, −23.2% [95% CI, −33.6% to −12.1%]).
Conclusions and Relevance
In this meta-analysis of patients with persistent asthma, the
use of single maintenance and reliever therapy compared with inhaled
corticosteroids as the controller therapy (with or without a long-acting
β-agonist) and short-acting β-agonists as the relief therapy was
associated with a lower risk of asthma exacerbations. Evidence for
patients aged 4 to 11 years was limited.
Full text:
Saturday, March 17, 2018
Exacerbations of COPD: prevention is still actual in 2018!!
Chronic obstructive pulmonary disease (COPD) is the third leading cause
of death worldwide. While COPD is a mainly chronic disease, a
substantial number of patients suffer from exacerbations. Severe
exacerbations are related to a significantly worse survival outcome.
This review summarises the current knowledge on the different aspects of
COPD exacerbations. The impact of risk factors and triggers such as
smoking, severe airflow limitation, bronchiectasis, bacterial and viral
infections and comorbidities is discussed. More severe exacerbations
should be treated with β-agonists and anticholinergics as well as
systemic corticosteroids.
Antibiotic therapy should only be given to
patients with presumed bacterial infection. Noninvasive ventilation is
indicated in patients with respiratory failure. Smoking cessation is key
to prevent further COPD exacerbations. Other aspects include choice of
pharmacotherapy, including bronchodilators, inhaled corticosteroids,
phosphodiesterase-4 inhibitors, long-term antibiotics and mucolytics.
Better education and self-management as well as increased physical
activity are important. Influenza and pneumococcal vaccination is
recommended. Treatment of hypoxaemia and hypercapnia reduce the rate of
COPD exacerbations, while most interventional bronchoscopic therapies
increase exacerbation risk within the first months after the procedure.
The prevention of exacerbations is one of the most important treatment
goals. To achieve that goal, patient education and smoking cessation
programmes as well as patient-tailored pharmacological and
nonpharmacological treatments are mandatory.
Full text:
Friday, March 9, 2018
2018 New approach for the treatment of severe uncontrolled asthma
New updated approach to severe uncontrolled asthma was presented by Greek team in ERJ Open research!!!
Asthma is a common, chronic and heterogeneous disease, affecting people of all ages. It may be mild, barely noticed by the patient, or it may range all the way to very severe disease, causing constant symptoms greatly affecting the life of the patient, and may result in poor quality of life and severe, life-threatening attacks.
A small subgroup of patients with asthma suffers from severe disease that is either partially controlled or uncontrolled despite intensive, guideline-based treatment. These patients have significantly impaired quality of life and although they constitute <5% of all asthma patients, they are responsible for more than half of asthma-related healthcare costs. Here, we review a definition for severe asthma and present all therapeutic options currently available for these severe asthma patients. Moreover, we suggest a specific algorithmic treatment approach for the management of severe, difficult-to-treat asthma based on specific phenotype characteristics and biomarkers.
Asthma is a common, chronic and heterogeneous disease, affecting people of all ages. It may be mild, barely noticed by the patient, or it may range all the way to very severe disease, causing constant symptoms greatly affecting the life of the patient, and may result in poor quality of life and severe, life-threatening attacks.
A small subgroup of patients with asthma suffers from severe disease that is either partially controlled or uncontrolled despite intensive, guideline-based treatment. These patients have significantly impaired quality of life and although they constitute <5% of all asthma patients, they are responsible for more than half of asthma-related healthcare costs. Here, we review a definition for severe asthma and present all therapeutic options currently available for these severe asthma patients. Moreover, we suggest a specific algorithmic treatment approach for the management of severe, difficult-to-treat asthma based on specific phenotype characteristics and biomarkers.
The diagnosis and
management of severe asthma requires specialised experience, time and
effort to comprehend the needs and expectations of each individual
patient and incorporate those as well as his/her specific phenotype
characteristics into the management planning. Although some new
treatment options are currently available for these patients, there is
still a need for further research into severe asthma and yet more
treatment options.
Full text:
Subscribe to:
Posts (Atom)





